Accordingly, we selected inhibitors of PSMA (2-PMPA) and Gal-3 (GB1107) that have shown effectiveness in inhibiting their respective targets for their application either independently or conjointly in the treatment of prostate cancer [24,25]. Here, LGALS3 is linked to prostate cancer.